MANAGING HEMOPHILIA COSTS

Hemophilia is a bleeding disorder in which a lack of naturally-occurring proteins called “clotting factor” reduces the body’s ability to control bleeding. It is extremely rare but treatment can be extremely expensive.

TREATMENT AND COSTS

To treat hemophilia, replacement therapy is used to artificially raise the level of clotting factor in a person’s blood via infusion. Concentrated forms of replacement clotting factor are available and can be self-administered at home. However, clotting factor concentrate is expensive and careful management and support for patients is essential.

Hemophilia Costs Vary With Severity

People with more severe cases of hemophilia require greater amounts of clotting factor to respond to bleeding episodes. 60% of patients have a severe form of hemophilia. In the most severe cases, people will need to use clotting factor to prevent bleeds, raising costs further. Total annual costs up to or more than $1 million per year for individual patients are not uncommon.

THE BRIOVARX THERAPY SOLUTIONS for HEMOPHILIA

To better understand how this comprehensive, patient-centric program works, let’s follow the journey of a new hemophilia patient, John.

1. PERSONALIZED PATIENT ONBOARDING
   When John’s prescription for hemophilia medicine is first received, a personalized patient onboarding begins. This process introduces John to the BriovaRx hemophilia team members and offers him personalized assistance navigating the entire specialty pharmacy process.

2. INITIAL ASSESSMENT
   The initial assessment identifies the severity and type of hemophilia John has, as well as his clinical history and hematological treatment information such as dosing regimens. The initial assessment will also include background on John’s joint health, level of physical activity and comorbidities.

3. ROUTINE ASSESSMENT
   Routine assessments work to confirm that John is taking his medications and that those medicines are not expired. In addition to verifying compliance, routine assessments help log John’s bleed history as well as hospital visits.

4. ONGOING CARE
   There is currently no cure for hemophilia and John will need support for life. The BriovaRx Hemophilia Therapy Solution model is designed to provide John with ongoing care and support. This proactive approach can include telephonic or video consultations with specialized pharmacists.

BriovaRx Therapy Solutions for Hemophilia and Bleeding Disorders ensure consistent management and holistic care coordination for patients with hemophilia.

This end-to-end service model helps keep patients healthy and lowers total cost of care. To learn more, contact your OptumRx representative.

THE 8th most costly specialty disease for employers

20,000 patients in the US


“A Million Dollar Patient in Perspective”: optum.com/optumrx

To accomplish better outcomes, the program relies upon a hemophilia pharmacy care team, dedicated pharmacists and team members closely tied to the hemophilia community.

All Optum trademarks and logos are owned by Optum, Inc. All other trademarks are the property of their respective owners.
©2019 Optum, Inc. All rights reserved.
MNINSUR-5/19 Optum, Inc. All rights reserved.


People with more severe cases of hemophilia require greater amounts of clotting factor to respond to bleeding episodes. 60% of patients have a severe form of hemophilia. In the most severe cases, people will need to use clotting factor to prevent bleeds, raising costs further. Total annual costs up to or more than $1 million per year for individual patients are not uncommon.